SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03907722

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

The 3q25 rs2305619 Polymorphism is Associated With Coronary Microvascular Obstruction Following Primary Angioplasty for Acute ST-segment Elevation Myocardial Infarction

The investigators enrolled 217 patients with acute STEMI undergoing primary PCI. The rs2305619 polymorphism was evaluated by real time PCR and plasma PTX3 concentration was assessed by human PTX3 ELISA kit.

NCT03907722 STEMI Microvascular Coronary Artery Disease
MeSH: Coronary Artery Disease Myocardial Ischemia Coronary Disease ST Elevation Myocardial Infarction
HPO: Coronary artery atherosclerosis

1 Interventions

Name: Long pentraxin 3

Description: Primary PCI

Type: Other

Genotypic variants


Primary Outcomes

Description: Percentage

Measure: Incidence of microvascular obstruction

Time: Immediate after pci

Secondary Outcomes

Description: Percentage

Measure: Incidence of mortality

Time: 30 days

Time Perspective: Cross-Sectional

Other


There is one SNP

SNPs


1 rs2305619

The 3q25 rs2305619 Polymorphism is Associated With Coronary Microvascular Obstruction Following Primary Angioplasty for Acute ST-segment Elevation Myocardial Infarction.

The 3q25 rs2305619 Polymorphism Associates With Microvascular Obstruction in STEMI The investigators enrolled 217 patients with acute STEMI undergoing primary PCI.

The rs2305619 polymorphism was evaluated by real time PCR and plasma PTX3 concentration was assessed by human PTX3 ELISA kit.

The rs2305619 polymorphism was evaluated by real time PCR and plasma PTX3 concentration was assessed by human PTX3 ELISA kit.



HPO Nodes


HPO:
Coronary artery atherosclerosis
Genes 34
TGFB2 TGFB3 TGFBR1 LDLRAP1 TGFBR2 MFAP5 APOA1 APOB ABCA1 MYH11 ELN LIPC FBN1 PRKG1 APOE PPARG ZMPSTE24 MYLK LMNA CYP7A1 SERPIND1 LDLR LOX MAT2A ABCG5 ABCG8 KCNJ5 ESR1 ZNF687 SMAD3 PCSK9 CEP19 ACTA2 FOXE3